New highly effective glycopeptide antibiotic for systemic use with bactericidal activity against a wide range of gram-positive (+) bacteria, multiresistant nosocomial strains, including VanB-phenotype VRE. It can be administered once daily intramuscularly or intravenously as a bolus injection. The antibiotic has low toxicity and favorable tolerability. It is used in treatment of serious respiratory and urinary tract infections, skin and soft tissue infections, bone and joint infections, septicemia, endocarditis, peritonitis, infectious colitis.
First antibiotic of the glycopeptide group. Highly active against a wide range of gram-positive (+) microorganisms, including methicillin-resistant strains.
Used in treatment of endocarditis, sepsis, skin and soft tissue infections, bone and joint infections (including osteomyelitis), CNS infections (including meningitis), infections of lower respiratory tract, pseudomembranous colitis, enterocolitis.